Mycophenolatemofetil for immunosuppression after liver transplantation: A follow-up study of 191 patients

Transplantation

Volumn 76, Issue 1, 2003, Pages 130-136

  Pfitzmann, Robert ^a   Klupp, Jochen ^a   Langrehr, Jan Michael ^a   Uhl, Mareen ^a   Neuhaus, Ruth ^a   Settmacher, Utz ^a   Steinmüller, Thomas ^a   Neuhaus, Peter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BONE MARROW TOXICITY; CHRONIC GRAFT REJECTION; DIARRHEA; FEMALE; FLAPPING TREMOR; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRAFT SURVIVAL; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0038638388     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000071522.74885.48     Document Type: Article

References (33)

1. The US Multicenter FK506 Liver Study Group: a comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
2. European FK506 Multicentre Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994; 344: 423.
3. Neuhaus P, Blumhardt G, Bechstein WO, et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. Transplantation 1995; 59: 31.
4. O'Grady JG, Burroughs A, Hardy P, et al. and The UK and Republic of Ireland Liver Transplant Study Group. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002; 360: 1119.
5. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK506-treated patients. Transplantation 1994; 58: 170.
6. Mueller AR, Platz KP, Schattenfroh N, et al. Neurotoxicity after orthotopic liver transplantation in cyclosporin A and FK506-treated patients. Transpl Int 1994; 7(Suppl 1): S37.
7. Herrero JI, Quiroga J, Sangro B, et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999; 5(5): 414.
8. Schlitt HJ, Barkmann A, Böker KHW, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587.
9. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Review. Immunopharmacology 2000; 47: 85.
10. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7(5): 442.
11. Hebert MF, Ascher NL, Lake JR, et al. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999; 67: 707.
12. Barkmann A, Nashan B, Schmidt HHJ, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000; 69: 1886.
13. McDiarmid SV. Mycophenolate mofetil in liver transplantation. Clin Transplant 1996; 10: 140.
14. Klupp J, Bechstein WO, Platz KP, et al. Mycophenolate mofetil added to immunosuppression after liver transplantation - first results. Transpl Int 1997; 10(3): 223.
15. Platz KP, Müller AR, Neuhaus P. Indications for mycophenolate mofetil therapy after liver transplantation. Transplant Proc 1997; 29(7): 2880.
16. Morris RE, Hoyt EG, Murphy MP, et al. Mycophenolic acid morphelino-ethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990; 22(4): 1659.
17. Platz KP, Sollinger HW, Hullett DA, et al. RS-61443 - a new potent immunosuppressive agent. Transplantation 1991; 51(1): 27.
18. Raisanen-Sokolowski A, Vuoristo P, Myllarniemi M, et al. Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl Immunol 1995; 3(4): 342.
19. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59(5): 655.
20. Fraser-Smith E, Rosete J, Schatzman R. Suppression by mycophenolate mofetil of the neointimal thickening caused by vascular injury in a rat arterial stenosis model. J Pharmacol Exp Ther 1995; 275(3): 1204.
21. Mathew TH for the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Results at three years. Transplantation 1998; 65(11): 1450.
22. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999; 68(3): 391.
23. Halloran P, Hathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997; 63: 39.
24. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66(4): 507.
25. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil (MMF). Lancet 1995; 345: 1321.
26. Klupp J, Glanemann M, Bechstein WO, et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Transplant Proc 31(1-2):1113, 1999.
27. Cai TH, Esterl Jr RM, Nichols L, et al. Improved immunosuppression with combination tacrolimus (FK 506) and mycophenolate acid in orthotopic liver transplantation. Transplant Proc 1998; 30: 1413.
28. Gavlik A, Demirbas A, Tsaroucha A, et al. Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up. Transplant Proc 1997; 29: 2971.
29. Eckhoff DE, McGuire BM, Frenette LR, et al. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998; 65(2): 180.
30. Platz KP, Mueller AR, Neuhaus R, et al. FK 506 and Mycophenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. Transplant Proc 1997; 29: 2872.
31. Stewart SF, Hudson M, Talbot T, et al. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357: 609.
32. Klupp J, Dambrin C, Hibi K, et al. Treatment by mycophenolate mofetil of advanced graft vascular disease in non-human primate recipients of orthotopic aortic allografts. Am J Transplant 2003 (in press).
33. Paterson DL, Singh N, Panebianco A, et al. Infections complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation 1998; 66(5): 593.